CORT Thesis Assessment
Corcept Therapeutics Incorporated
CORT's market price of $45.10 appears to be consistent with the fundamental value indicated by this analysis.
The prediction ensemble collectively suggests CORT's current $45.10 price appears roughly consistent with fundamental value when accounting for both the near-term transition risks and the tail-option value embedded in pipeline and balance sheet. The most informative near-term question (FDA resubmission path by 2026-06-30) resolves modestly in favor of the bull case at 55%, and the Korlym scripts-tablets gap closure is approximately coin-flip at 50%. However, the Lifyorli Year 1 bull case (>$50M annualized by Q3 2026 10-Q) reads at only 38% - meaningfully below management's implicit expectation and below the market's embedded credit. The low-probability tail-risk markets (third-party ANDA at 25%, sub-$40 insider sales at 35%, MONARCH hit at 28%) collectively keep the thesis honest without tilting strongly in either direction. The price has appreciated from $34.64 at analysis-date to $45.10, absorbing about half of the Myth Meter UNDERPRICED gap. The residual appears consistent with reasonable uncertainty about timing and execution.
What the Markets Suggest
The CORT prediction ensemble paints a picture of a company in forced transition whose price has substantially re-rated between analysis date ($34.64) and current ($45.10) - absorbing approximately half of the original Myth Meter UNDERPRICED gap identified in the lens committee. The thesis posture accordingly shifts from clearly underpriced to approximately fairly priced, with directional bets now more symmetric.
The two highest-information-gain markets tell offsetting stories. The FDA resubmission path market at 55% modestly favors the bull case - consistent with industry base rates for specialty orphan NDAs with existing Phase 3 data, supported by Corcept's revealed-preference signals (60 to 175 endocrinology rep buildout only makes economic sense under resubmission assumption) and Lifyorli's 4-month PDUFA acceleration demonstrating functional FDA-Corcept relationship. A favorable resolution by 2026-06-30 would reduce ELEVATED regulatory exposure and preserve the $3-5B Cushing's relacorilant forecast. Conversely, the Lifyorli Year 1 execution market at 38% tilts against the bull case on near-term timing - center activation, Medicare J-code assignment, and combination-therapy coordination typically produce back-loaded ramps that don't fully surface until Q4 2026 or early 2027.
The tail-risk markets collectively provide downside protection. Third-party ANDA filing probability at 25% (high 93% agreement) reflects consensus that Teva's own non-entry is a strong revealed-preference signal against generic economics post-AG compression. Sub-$40 insider sales at 35% lean against MISALIGNED governance escalation. MONARCH MASH P2b hit at 28% is appropriately skeptical given MASH Phase 2b base rates and SGRA class safety concerns, but a positive readout would be genuine upside.
The 4th guide-cut probability at 35% is notably below prior-cycle base rates (which would suggest 50%+), reflecting the fact that the $900M-$1B FY26 guide was issued AFTER both the Cushing's CRL and Q4 2025 pharmacy disruption - already absorbing the known negatives that drove prior cuts. The scripts-tablets gap market at exactly 50% captures the genuine uncertainty about whether Q4 2025 pharmacy transition was transitory or structural, which is the cleanest near-term operational diagnostic.
Taking these signals together, CORT's current price of $45.10 appears roughly consistent with fundamental value. The thesis direction from here depends primarily on FDA meeting outcome disclosure timing (June 2026) and Q2-Q3 2026 Lifyorli launch visibility. A favorable resolution of both would support continued upward pressure; unfavorable resolution of either would likely produce downward pressure, with the $532M cash cushion + zero debt preventing tail compression to the $27-32 acquisition-attractor range identified in Black Swan Beacon. The price appears at value - neither compelling the UNDERPRICED thesis nor confirming a persistent mispricing.
Market Contributions7 markets
This is the highest-information-gain market and the single most binary event in the near term. At 55% probability of resubmission path, the ensemble leans modestly favorable - consistent with industry base rates for specialty orphan NDAs with existing Phase 3 data, supported by revealed-preference signals (SG&A 60-to-175 rep buildout) and Lifyorli's 4-month PDUFA acceleration. A favorable resolution would reduce ELEVATED regulatory exposure, preserve $80-150M of SG&A buildout as productive, and validate the $3-5B Cushing's relacorilant forecast. An unfavorable resolution would strand SG&A and force durability re-rating.
At 38% probability, the ensemble is meaningfully skeptical that Lifyorli reaches $50M annualized by Q3 2026 10-Q (requires $12.5M+ in Q3 alone). Q3 2026 is only the second full post-approval quarter, first-ever Corcept oncology launch, center activation typically takes 6-12 months, and the CFO's own 'only a small portion' framing implies back-loaded ramp. This does not invalidate the Lifyorli moat thesis - full-year $50M+ is more likely probability - but it tempers the expectation that the UNDERPRICED reading resolves quickly. The market's ~$200M credit for Lifyorli (vs $500M-$2B typical comparable) may prove right in the near term and wrong over 18-24 months.
At 35% probability, the ensemble leans against a 4th consecutive guide cut within 6 months of the FY26 guide issuance. The key insight is that the $900M-$1B range was issued AFTER the Cushing's CRL and Q4 2025 pharmacy disruption, already incorporating known negatives. A cut below $900M would require new structurally negative information. Management narrative discipline plus the $532M cash cushion removing defensive pressure to cut both lower the probability. However, the three-prior-cut pattern and GAP_BULLISH management rhetoric keep the probability meaningful.
At exactly 50% probability (coin-flip), this market captures the central unresolved question about whether Q4 2025 pharmacy transition was transitory or structural. The offsetting forces are balanced: typical vendor transitions stabilize in 1-2 quarters (pro) versus AG mix shift creating a structural 5-10pp ASP-based gap (con) plus 2 additional pharmacy onboardings during 2026 adding friction. Baker's $3.3M open-market purchase at $33.14 AFTER the disruption disclosure is a revealed-preference signal toward transitory. This market's resolution in May 2026 will be the earliest real data point.
At only 25% probability with high model agreement (93%), the ensemble strongly discounts near-term third-party ANDA filings on mifepristone. The economic case is weak: AG at 78% volume share at 30% WAC discount has already absorbed most generic-substitutable value, leaving thin margins for a new entrant. Teva's own non-entry despite winning the Fed Cir litigation is the strongest revealed-preference signal. This provides meaningful downside protection - the most feared Gravy Gauge FRAGILE deepening scenario is unlikely to materialize in 2026.
At 35% probability, the ensemble leans against sub-$40 Form 4 executions by the CFO and endocrinology president under their post-CRL 10b5-1 plans. Rational plan design under Ritchie derivative suit scrutiny would typically include floors above $40 to avoid MISALIGNED optics escalation. Current $45 stock price reduces sub-$40 execution probability further. However, plans that are time-based or have low floors would have already executed at sub-$40 during March-April 2026 when the stock traded in the $33-45 range. A sub-$40 execution would meaningfully escalate the governance read but does not by itself invalidate the thesis.
At 28% probability, the ensemble is appropriately skeptical of a clean Phase 2b hit in MASH by year-end 2026. MASH Phase 2b base rates are structurally low (~35-45%), trial timing slippage is typical (2-4 months), and the strict 'clean safety' requirement acts as a filter given SGRA class ALT-elevation concerns. A positive readout would be a meaningful upside surprise beyond the current thesis but is not the base case. A miss or slip doesn't invalidate the pipeline thesis - miricorilant is optional indication expansion, not the core bull case.
Balancing Factors
FDA resubmission path probability of 55% is modestly favorable for the bull thesis and represents the highest-information-gain near-term event
Third-party ANDA probability at only 25% removes the most feared Gravy Gauge FRAGILE-deepening scenario from the near-term downside case
Balance sheet ($532M cash, zero debt, $142M FCF) provides 4-5 year runway under stress and prevents tail compression into the $27-32 acquisition-attractor range
Lifyorli approval was 4 months ahead of PDUFA, demonstrating functional FDA-Corcept relationship and pulling launch timeline forward
Baker director $3.3M open-market buy at $33.14 on 2026-03-17 is substantive alignment signal that the three-lens committee reads as not credited by the market at analysis time
Guide cut probability of 35% is below prior-cycle base rates because the FY26 $900M-$1B range was issued AFTER the CRL and pharmacy disruption, already absorbing known negatives
Key Uncertainties
FDA Type B meeting outcome in April 2026 and whether disclosure occurs by 2026-06-30 - the single most binary near-term event
Whether Q4 2025 pharmacy transition disruption was transitory or structural - Q1 2026 10-Q (May 2026) is the first diagnostic data point
Lifyorli launch pacing in first two full quarters post-approval - whether infrastructure-readiness (oncology commercial team built in 2025) translates to faster-than-typical center activation
Whether third-party generic manufacturers may have been developing ANDAs in parallel with Teva's litigation (pre-developed filings could surface within the 10-month window)
Plan structure for Maduck and Mokari 10b5-1 plans - specifically whether price floors were designed above $40 to avoid MISALIGNED optics
MONARCH MASH Phase 2b primary endpoint specifics and whether timing slips from end-2026 to Q1 2027 (common for MASH imaging trials)
Whether the Myth Meter UNDERPRICED gap has been fully resolved by the price appreciation from $34.64 to $45.10, or whether residual mispricing remains
The price has already absorbed a meaningful portion of the post-analysis Myth Meter UNDERPRICED gap (price rose from $34.64 at analysis date to $45.10 current). Further upside is contingent on FDA resubmission path confirmed by 2026-06-30 AND Lifyorli execution visible in Q2-Q3 2026 disclosures. Downside pressure is primarily from a potential 4th FY26 guide cut (35%) or sub-$40 insider sales (35%). The thesis direction from here is more symmetric than at the original $34.64 analysis price.
Confidence note: Model agreement across all 7 markets is high (92-94%), indicating genuine analytical consensus rather than averaging of divergent views. However, confidence is capped at MEDIUM because: (1) the three highest-information-gain markets (FDA path, Lifyorli run-rate, Q1 scripts-tablets gap) are all near coin-flip territory, meaning the thesis direction is sensitive to resolution of any single market; (2) a material re-rating requires multiple favorable resolutions stacking, which is probabilistically uncommon; (3) the Myth Meter UNDERPRICED signal that drove the initial analysis has partially resolved via price appreciation from $34.64 to $45.10 between analysis date and current date, shifting the thesis posture from clearly underpriced to fairly priced.
This assessment synthesizes probabilistic forecasts from an AI model ensemble for educational and informational purposes only. Model outputs may contain errors, hallucinations, or data lag. It does not constitute financial advice, a recommendation to buy or sell securities, or a guarantee of future outcomes. Past model performance does not predict future accuracy. Investors should conduct their own research and consult qualified financial advisors before making investment decisions.